This page connects to the broader neurodegenerative disease knowledge graph:
- Diseases: [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), ALS, FTD, [Huntington's disease](/diseases/huntingtons-disease), PSP, MSA
- Brain regions: [substantia nigra](/brain-regions/substantia-nigra), striatum, motor cortex, hippocampus, frontal cortex
- Cell types: [dopaminergic neurons](/cell-types/mesencephalic-dopaminergic-neurons), [astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia), motor neurons, oligodendrocytes
- Proteins/Genes: tau, [alpha-synuclein](/proteins/alpha-synuclein), TDP-43, SNCA, GBA, LRRK2, C9orf72, HTT
- Mechanisms: [neuroinflammation](/mechanisms/neuroinflammation), [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), [lysosomal dysfunction](/mechanisms/lysosomal-dysfunction), [protein aggregation](/mechanisms/protein-aggregation), [oxidative stress](/mechanisms/oxidative-stress), [autophagy](/mechanisms/autophagy), [synaptic dysfunction dysfunction](/mechanisms/synaptic dysfunction-dysfunction)
- Therapeutics: [gene therapy](/therapeutics/gene-therapy-neurodegeneration), ASOs, CRISPR gene editing, deep brain stimulation
- Pathways: complement system, neurotrophic signaling, cell death pathways
This therapeutic strategy targets gasdermin proteins — the executioners of pyroptosis, a highly inflammatory form of programmed cell death increasingly implicated in neurodegenerative disease progression. Unlike apoptosis, pyroptosis involves gasdermin D (GSDMD) and gasdermin E (GSDME/DFNA5) forming membrane pores that release inflammatory cytokines (IL-1β, IL-18) and alarmins, driving chronic neuroinflammation and neuronal loss. In Alzheimer's disease, Parkinson's disease, and ALS, repeated sub-lethal pyroptotic activation creates a self-perpetuating inflammatory loop that accelerates disease progression.
- Primary Target: GSDMD catalytic domain (pore-forming domain) or GSDME
- Target Type: Small-molecule inhibitor, peptide inhibitor, or antibody blocking oligomerization
- Expression: Expressed in microglia, astrocytes, and neurons; upregulated in disease states
- Localization: Cytoplasmic protein; active cleaved fragments translocate to plasma membrane
Pyroptosis is a highly inflammatory cell death modality distinct from apoptosis. While cGAS-STING inhibition blocks the upstream type I interferon response, gasdermin inhibition blocks a parallel inflammatory axis driven by caspase-1/caspase-4/5 activation:
- NLRP3 inflammasome activation: In neurodegeneration, aggregated proteins (amyloid-beta, tau, alpha-synuclein), mitochondrial DAMPs, and damaged mitochondria activate NLRP3 → caspase-1
- Gasdermin cleavage: Active caspase-1 cleaves GSDMD (and GSDME in some cell types) into N-terminal (pore-forming) and C-terminal (inhibitory) fragments
- Membrane pore formation: GSDMD-NT oligomerizes at the plasma membrane, forming 10-20nm pores
- Inflammatory release: IL-1β and IL-18 (pre-formed and activated by caspase-1) are released through pores; cellular swelling leads to lysis
- Chronic neuroinflammation: Released alarmins (HMGB1, ATP, S100A8/A9) propagate inflammation to neighboring cells
Critically, GSDMD knockout mice show dramatically reduced neuroinflammation in AD and PD models, making this a high-value target with strong genetic validation.
flowchart TD
A["Aβ/Tau/α-Syn Aggregates"] --> B["NLRP3 Inflammasome Activation"]
C["Mitochondrial DAMPs"] --> B
D["TLR Activation by Pathogen-Associated Patterns"] --> B
B --> E["Caspase-1 Activation"]
E --> F["GSDMD Cleavage"]
E --> G["IL-1β/IL-18 Processing"]
F --> H["GSDMD-NT Oligomerization"]
H --> I["Membrane Pore Formation"]
G --> J["Cytokine Release via Pores"]
I --> K["Cell Swelling & Lysis"]
J --> L["Chronic Neuroinflammation"]
K --> L
M["GSDMD Inhibitor"] -->|"Blocks"| H
N["Disulfiram"] -->|"Blocks"| F
style M fill:#4CAF50,color:white
style N fill:#4CAF50,color:white
style L fill:#f44336,color:white
Cross-links to relevant mechanisms:
- Pyroptosis in Neurodegeneration
- NLRP3 Inflammasome
- Neuroinflammation
- Inflammasome Activation
- Caspase-1 in Neurodegeneration
- Microglia and Neuroinflammation
- Astrocyte Reactivity
| Dimension |
Score |
Rationale |
| Novelty |
8/10 |
Gasdermin inhibitors are actively researched in oncology but virtually unexplored for neurodegeneration; GSDMD knockout mice show dramatic neuroprotection |
| Mechanistic Rationale |
9/10 |
Strong genetic validation (GSDMD KO mice protected); pathway intersects with multiple neurodegenerative mechanisms (NLRP3, cGAS-STING, mitochondrial dysfunction) |
| Addresses Root Cause |
7/10 |
Blocks inflammatory cell death but not upstream aggregation; addresses "secondary damage" from proteinopathy |
| Delivery Feasibility |
7/10 |
Small molecules like disulfiram and dimethyl fumarate cross BBB; novel GSDMD inhibitors in development |
| Safety Plausibility |
8/10 |
GSDMD KO mice are viable and healthy; pyroptosis inhibition may reduce infection risk but less severe than STING inhibition |
| Combinability |
9/10 |
Highly orthogonal to anti-aggregation therapies; combines well with NLRP3 inhibitors, cGAS-STING blockers, and neuroprotective approaches |
| Biomarker Availability |
7/10 |
CSF IL-1β, IL-18, and GSDMD cleavage products can be measured; less validated than IFN signature |
| De-risking Path |
8/10 |
GSDMD KO mice protected in AD/PD models; disulfiram is FDA-approved for other uses; tool compounds available |
| Multi-disease Potential |
9/10 |
Validated in AD, PD, ALS, FTD, and aging; pyroptosis is a common endpoint across proteinopathies |
| Patient Impact |
8/10 |
Reducing chronic neuroinflammation from pyroptotic cell death could significantly slow progression |
| Total |
80/100 |
|
- Phase 1 — Lead identification: Screen FDA-approved drugs (disulfiram, dimethyl fumarate) and natural products for GSDMD inhibition; develop high-throughput GSDMD cleavage assay
- Phase 2 — Optimization: Medicinal chemistry to improve potency and BBB penetration; structure-activity relationship on disulfiram analogs
- Phase 3 — Cellular validation: Test in iPSC-derived microglia and neurons exposed to Aβ42, tau, or α-syn; measure IL-1β release, pyroptosis markers, and cell survival
- Phase 4 — Model efficacy: Test in 5xFAD mice (AD), α-syn pre-formed fibril mice (PD), and SOD1-G93A mice (ALS); measure neuroinflammation and behavioral outcomes
- Phase 5 — Safety: Chronic toxicology in rodents and non-human primates; assess infection susceptibility during extended dosing
| Disease |
Relevance |
Rationale |
| Alzheimer's Disease |
High |
Aβ activates NLRP3 → GSDMD cleavage; GSDMD KO reduces inflammation and improves cognition in APP/PS1 mice |
| Parkinson's Disease |
High |
α-syn oligomers activate NLRP3; GSDMD-mediated inflammation contributes to dopaminergic neuron loss |
| ALS/FTD |
High |
TDP-43 and SOD1 mutations activate inflammasome; GSDMD cleavage detected in ALS patient spinal cord |
| Frontotemporal Dementia |
Medium |
Tau pathology activates pyroptosis pathway; limited patient data but strong mechanistic rationale |
| Aging/Inflammaging |
High |
Age-related DAMPs accumulate and trigger chronic low-level pyroptosis |
| PSP |
Medium |
4R tauopathy with neuroinflammation component; GSDMD role being characterized |
- With NLRP3 inhibitors (MCC950, dapansutrile): Block upstream inflammasome activation while also inhibiting downstream gasdermin pore formation — dual inhibition for maximum anti-inflammatory effect
- With cGAS-STING inhibitors: Address both DNA-sensing (cGAS-STING) and protein-aggregation-sensing (NLRP3-GSDMD) inflammatory pathways simultaneously
- With anti-aggregation therapies: Reduce inflammatory "fuel" from protein aggregates while blocking the inflammatory response to whatever aggregates remain
- Pyroptosis in Neurodegeneration | NLRP3 Inflammasome
- Gasdermin Family | GSDMD Protein
- Neuroinflammation | Neuroinflammation Pathway
- Microglia and Neuroinflammation
- Inflammasome Activation
- cGAS-STING Pathway Inhibition — complementary approach
- NLRP3 Senomorphic Cycling — upstream target
- Objective: Repurpose FDA-approved GSDMD inhibitors
- Activities:
- Screen approved drugs for GSDMD inhibition (disulfiram, dimethyl fumarate, clomipramine)
- Develop GSDMD cleavage ELISA for drug screening
- In vitro potency determination
- Estimated Cost: $500K-1M
- Milestone: 2-3 compounds with micromolar GSDMD inhibition and favorable PK
- Objective: Advance leads to preclinical candidates
- Activities:
- SAR on disulfiram analogs to improve potency and reduce off-target effects
- BBB penetration optimization
- iPSC microglia/neuron efficacy testing
- Estimated Cost: $2-3M
- Milestone: Lead compound with nM potency and demonstrated neuroprotection in vitro
- Objective: GLP toxicology and IND-enabling studies
- Activities:
- 28-day and 90-day toxicology in rodents
- PK/PD in AD/PD mouse models
- Formulation development for oral dosing
- Estimated Cost: $3-5M
- Milestone: IND-ready package with GLP toxicology
- Objective: First-in-human studies
- Activities:
- Phase 1 dose-escalation in healthy volunteers
- Phase 2a in early AD or PD patients
- CSF biomarker validation (IL-1β, GSDMD cleavage products)
- Estimated Cost: $8-15M
- Milestone: Phase 1 safety data and biomarker modulation in patients
- Immediate (Week 1-2): Contract research organization to screen FDA-approved drug library for GSDMD inhibition using established cleavage assay
- Short-term (Month 1-2): Establish iPSC-derived microglia and neuronal cultures from AD/PD patients for in vitro screening
- Medium-term (Month 2-4): Engage with academic collaborators (e.g.,Dr. Christian Y. Lee, MIT) for access to GSDMD KO mice
- Partnership (Month 4-8): Identify pharma partner with neuroinflammation franchise for co-development; target companies with existing NLRP3 programs (e.g., Roche, Novartis)
- Alzheimer's Disease — GSDMD-mediated neuroinflammation
- Parkinson's Disease — α-synuclein-induced pyroptosis
- ALS — TDP-43 and SOD1-driven inflammasome activation
- Frontotemporal Dementia — Tau-driven pyroptosis
- Pyroptosis — Primary therapeutic target
- NLRP3 Inflammasome — Upstream activator of GSDMD
- Neuroinflammation — Downstream consequence
- Inflammasome Activation — Pathway to pyroptosis
- Cell Death Pathways — Comparison with apoptosis and necroptosis
- cGAS-STING Pathway Inhibition — Complementary neuroinflammation target
- NLRP3 Senomorphic Cycling Therapy — Upstream inflammasome inhibition
- CD38 Inhibition + NAD+ Synergy — Addresses inflammatory metabolism